METHODS: A series of measures and performance standards were reviewed and developed by a Blue-Ribbon Panel of lung cancer experts in conjunction with ASTRO in 2022. As part of this initiative, quality, surveillance, and aspirational metrics were developed for (1) initial consultation and workup; (2) simulation, treatment planning, and treatment delivery; and (3) follow-up. The DVH metrics for target and organ-at-risk treatment planning dose constraints were also reviewed and defined.
RESULTS: Altogether, a total of 19 lung cancer quality metrics were developed. There were 121 DVH constraints developed for various fractionation regimens, including ultrahypofractionated (1, 3, 4, or 5 fractions), hypofractionated (10 and 15 fractionations), and conventional fractionation (30-35 fractions).
CONCLUSIONS: The devised measures will be implemented for quality surveillance for veterans both inside and outside of the VA system and will provide a resource for lung cancer-specific quality metrics. The recommended DVH constraints serve as a unique, comprehensive resource for evidence- and expert consensus-based constraints across multiple fractionation schemas.
方法:2022年,蓝带肺癌专家小组与ASTRO一起审查并制定了一系列措施和性能标准。作为这一举措的一部分,质量,监视,并为a)初步咨询和工作制定了理想的指标,b)模拟,治疗计划,和治疗交付,andc)FollowUp.还审查并定义了靶和器官风险治疗计划剂量限制的DVH指标。
结果:总之,共制定了19项肺癌质量指标.有121DVH约束开发各种分馏方案,包括超分割(1,3,4,5馏分[s]),高分馏(10和15分馏),和常规分馏(30-35馏分)。
结论:所设计的措施将用于退伍军人系统内外的质量监测,以及为肺癌特定的质量指标提供资源。推荐的DVH约束作为一个独特的,跨多个分割模式的综合证据资源和基于专家共识的约束。